Oncopeptides AB: Oncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufen
STOCKHOLM, Oct. 26, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (NASDAQ Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological
United States United Kingdom Castillay Leรณp European Commission Drug Administration Global Head Of Corporate Communications
Source: finanznachrichten.de